Literature DB >> 18816183

Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms.

Yongchun Wang1, Jeanne Kowalski, Hua-Ling Tsai, Radharani Marik, Nijaguna Prasad, Helina Somervell, Pang-Kuo Lo, Lauren E Sangenario, Lars Dyrskjot, Torben F Orntoft, William H Westra, Alan K Meeker, James R Eshleman, Christopher B Umbricht, Martha A Zeiger.   

Abstract

BACKGROUND: Although fine-needle aspiration (FNA) biopsy of thyroid nodules is very sensitive in detecting thyroid malignancy, it remains ambiguous in 20-30% of cases. Current biomarkers for thyroid cancer lack either the sensitivity or specificity to substantially address this clinical problem. The aim of this study was to investigate the gene expression patterns of human telomerase reverse transcriptase (hTERT) alternative splice variants in benign and malignant thyroid tumors in an attempt to find a more reliable biomarker in the differential diagnosis of thyroid nodules.
METHODS: One hundred and thirty-three thyroid tumors from eight histopathological tumor types were collected from patients undergoing thyroid surgery at Johns Hopkins Hospital. Gene expression patterns of hTERT alternative splice variants were investigated in the tumors by nested reverse transcriptase-PCR. Telomerase enzyme activity was evaluated in a subset of 16 samples associated with the different hTERT patterns. Association of c-myc expression and hTERT patterns was also examined.
RESULTS: Malignant thyroid tumors exhibited a greater proportion of the active full-length hTERT transcript (0.57 +/- 0.15) than inactive splice variants, alpha(-) (0.13 +/- 0.02), or beta(-)/alpha(-)beta(-) deletion transcripts (0.30 +/- 0.11; p < 0.001). The opposite was observed in benign tumors, which exhibited greater proportions of beta(-)/alpha(-)beta(-) deletion transcripts (0.64 +/- 0.08) than either the full-length (0.19 +/- 0.06) or alpha(-) deletion transcripts (0.17 +/- 0.02; p < 0.001). Similar results were observed among a diagnostically challenging subset of 50 thyroid tumors that were suspicious for malignancy on FNA. Further, increased telomerase enzymatic activity was only associated with expression of the full-length hTERT isoform. In contrast, c-myc expression, which has been implicated in hTERT regulation, correlated with overall hTERT transcription without specificity for expression of the full-length isoform.
CONCLUSIONS: These differences in gene expression patterns of hTERT alternative splice variants may provide a useful adjunct to FNA diagnosis of suspicious thyroid tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18816183      PMCID: PMC2857449          DOI: 10.1089/thy.2008.0101

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  41 in total

Review 1.  Progress in the preoperative diagnosis of thyroid nodules: managing uncertainties and the ultimate role for molecular investigation.

Authors:  J I Mechanick; A Carpi
Journal:  Biomed Pharmacother       Date:  2006-08-01       Impact factor: 6.529

2.  Validation of a five-tier cytodiagnostic system for thyroid fine needle aspiration biopsies using cytohistologic correlation.

Authors:  Brian J Yoder; Rachel Redman; Nicole A Massoll
Journal:  Thyroid       Date:  2006-08       Impact factor: 6.568

Review 3.  Follicular thyroid lesions, elements that affect both diagnosis and prognosis.

Authors:  Martha A Zeiger; Alan P B Dackiw
Journal:  J Surg Oncol       Date:  2005-03-01       Impact factor: 3.454

4.  Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT).

Authors:  Yasuhiro Ito; Hiroshi Yoshida; Chisato Tomoda; Takashi Uruno; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  Anticancer Res       Date:  2005 Jan-Feb       Impact factor: 2.480

5.  Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues.

Authors:  Yidong Fan; Zhaoxu Liu; Xiaolei Fang; Zheng Ge; Nan Ge; Yong Jia; Peng Sun; Fenglan Lou; Magnus Björkholm; Astrid Gruber; Peter Ekman; Dawei Xu
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

6.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.

Authors:  T R Golub; D K Slonim; P Tamayo; C Huard; M Gaasenbeek; J P Mesirov; H Coller; M L Loh; J R Downing; M A Caligiuri; C D Bloomfield; E S Lander
Journal:  Science       Date:  1999-10-15       Impact factor: 47.728

Review 7.  Aberrant and alternative splicing in cancer.

Authors:  Julian P Venables
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

8.  Telomerase activity in thyroid fine needle aspirates.

Authors:  Josefina Mora; Enrique Lerma
Journal:  Acta Cytol       Date:  2004 Nov-Dec       Impact factor: 2.319

Review 9.  Follicular neoplasms of the thyroid: what to recommend.

Authors:  Tobias Carling; Robert Udelsman
Journal:  Thyroid       Date:  2005-06       Impact factor: 6.568

Review 10.  Alterations of pre-mRNA splicing in cancer.

Authors:  Zane Kalnina; Pawel Zayakin; Karīna Silina; Aija Linē
Journal:  Genes Chromosomes Cancer       Date:  2005-04       Impact factor: 5.006

View more
  15 in total

1.  Antiretroviral therapy-induced toxicity is associated with increased mRNA expression of telomerase.

Authors:  Min Li; Yram Foli; Nana Y Amakye; Taline Klein; Shanmugapriya Selvaraj; Lingeng Lu; Elijah Paintsil
Journal:  J Clin Pharmacol       Date:  2015-05-28       Impact factor: 3.126

Review 2.  Telomerase and the endocrine system.

Authors:  Furio Pacini; Silvia Cantara; Marco Capezzone; Stefania Marchisotta
Journal:  Nat Rev Endocrinol       Date:  2011-03-29       Impact factor: 43.330

3.  Telomere length is related to alternative splice patterns of telomerase in thyroid tumors.

Authors:  Yongchun Wang; Alan K Meeker; Jeanne Kowalski; Hua-Ling Tsai; Helina Somervell; Christopher Heaphy; Lauren E Sangenario; Nijaguna Prasad; William H Westra; Martha A Zeiger; Christopher B Umbricht
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

4.  Summary statement: utility of molecular marker testing in thyroid cancer.

Authors:  Linwah Yip; Electron Kebebew; Mira Milas; Sally E Carty; Thomas J Fahey; Sareh Parangi; Martha A Zeiger; Yuri E Nikiforov
Journal:  Surgery       Date:  2010-12       Impact factor: 3.982

5.  Telomeres and thyroid cancer.

Authors:  Marco Capezzone; Stefania Marchisotta; Silvia Cantara; Furio Pacini
Journal:  Curr Genomics       Date:  2009-12       Impact factor: 2.236

6.  Alternative splicing regulation of telomerase: a new paradigm?

Authors:  Mandy S Wong; Woodring E Wright; Jerry W Shay
Journal:  Trends Genet       Date:  2014-08-26       Impact factor: 11.639

Review 7.  Alternative RNA splicing and cancer.

Authors:  Sali Liu; Chonghui Cheng
Journal:  Wiley Interdiscip Rev RNA       Date:  2013-06-13       Impact factor: 9.957

8.  Quantification of alternative splicing variants of human telomerase reverse transcriptase and correlations with telomerase activity in lung cancer.

Authors:  Yan Liu; Bing-quan Wu; Hao-hao Zhong; Xin-xia Tian; Wei-gang Fang
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

Review 9.  Human telomerase activity regulation.

Authors:  Aneta Wojtyla; Marta Gladych; Blazej Rubis
Journal:  Mol Biol Rep       Date:  2010-11-18       Impact factor: 2.316

10.  Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage.

Authors:  María García-Beccaria; Paula Martínez; Marinela Méndez-Pertuz; Sonia Martínez; Carmen Blanco-Aparicio; Marta Cañamero; Francisca Mulero; Chiara Ambrogio; Juana M Flores; Diego Megias; Mariano Barbacid; Joaquín Pastor; Maria A Blasco
Journal:  EMBO Mol Med       Date:  2015-07       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.